Genomics Reporting Implementation Guide
3.0.0 - release International flag

Genomics Reporting Implementation Guide, published by HL7 International / Clinical Genomics. This guide is not an authorized publication; it is the continuous build for version 3.0.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/genomics-reporting/ and changes regularly. See the Directory of published versions

: PGxRecEx05 - XML Representation

Raw xml | Download


<Task xmlns="http://hl7.org/fhir">
  <id value="PGxRecEx05"/>
  <meta>
    <profile
             value="http://hl7.org/fhir/uv/genomics-reporting/StructureDefinition/followup-recommendation"/>
  </meta>
  <text>
    <status value="generated"/>
    <div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: Task PGxRecEx05</b></p><a name="PGxRecEx05"> </a><a name="hcPGxRecEx05"> </a><a name="PGxRecEx05-en-US"> </a><p><b>status</b>: Requested</p><p><b>intent</b>: proposal</p><p><b>code</b>: <span title="Codes:{http://loinc.org LA26422-8}">Decrease dose</span></p><p><b>description</b>: For amitriptyline, a 50% reduction in starting dose is recommended with therapeutic drug monitoring to guide dose adjustment. Refer to current guidelines for dosage and recommendations at https://cpicpgx.org/guidelines/guideline-for- tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/. If CYP2D6 genotyping is available, refer to the current guidelines for dosing recommendations.</p><p><b>for</b>: <a href="Patient-CGPatientExample01.html">Adam B. Everyman  Male, DoB: 1951-01-20 ( Medical Record Number: m123 (use: usual, ))</a></p><p><b>reasonReference</b>: <a href="Observation-TxImp05.html">Poor metabolizer</a></p></div>
  </text>
  <status value="requested"/>
  <intent value="proposal"/>
  <code>
    <coding>
      <system value="http://loinc.org"/>
      <code value="LA26422-8"/>
      <display value="Decrease dose"/>
    </coding>
  </code>
  <description
               value="For amitriptyline, a 50% reduction in starting dose is recommended with therapeutic drug monitoring to guide dose adjustment. Refer to current guidelines for dosage and recommendations at https://cpicpgx.org/guidelines/guideline-for- tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/. If CYP2D6 genotyping is available, refer to the current guidelines for dosing recommendations."/>
  <for>🔗 
    <reference value="Patient/CGPatientExample01"/>
  </for>
  <reasonReference>🔗 
    <reference value="Observation/TxImp05"/>
    <display value="Poor metabolizer"/>
  </reasonReference>
</Task>